Angiopoietin-1 in the treatment of ischemia and sepsis.
Angiogenic factors have been the focus of a great deal of research for the treatment of ischemic diseases. Described just more than 10 years ago, angiopoietin 1 (Ang-1) has shown promising results in I/R models. Angiopoietin 1 is essential for both embryonic vasculogenesis and adult angiogenesis. Because of its role in maturation of vessels, it seems well suited to complement the angiogenic factor vascular endothelial growth factor (VEGF), which has been shown to induce vascular budding but in isolation produces nonfunctional vessels. This review will focus on (1) Ang-1 and its receptor, Tie-2, and the resultant intracellular signaling cascade; (2) the complex relationship of Ang-1 and VEGF; (3) the results of Ang-1 in I/R and sepsis models; (4) the results of combination (Ang-1 and VEGF) therapies in I/R and sepsis models; and (5) delivery mechanisms for angiogenic factors to ischemic heart.
Novotny
Nathan M
NM
Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Lahm
Tim
T
Markel
Troy A
TA
Crisostomo
Paul R
PR
Wang
Meijing
M
Wang
Yue
Y
Tan
Jiangning
J
Meldrum
Daniel R
DR
D042683:Angiopoietin-1 / Q000502:physiology / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D007511:Ischemia / Q000188:drug therapy*; D051379:Mice; D018345:Mice, Knockout; D023421:Models, Animal; D018919:Neovascularization, Physiologic; D018805:Sepsis / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
C467630:ANGPT1 protein, human; D042683:Angiopoietin-1; D042461:Vascular Endothelial Growth Factor A